Moderna's CEO on why he doesn't think waiving IP will increase mRNA vaccine supply: “If someone wants to start from scratch, they would have to figure out how to make mRNA, which is not in our patents.”

Right there, in black and white, are a few very important things. (1/10)
1. It confirms that Moderna’s statement in Oct 2020 about waiving patents was just PR stunt.

They deliberately left out the tech transfer part, and are saying here that the patents they would release wouldn’t be helpful anyways.
2. #TRIPsWaiver is only a prerequisite for expanding global manufacturing capacity.

It'll all come down to the details, and w/out tremendous pressure/scrutiny from the movement that made this happen in the first place those negotiations will ensure nothing substantive is done.
3. Drugmakers like Moderna will not do anything that comprises a dollar of their profits unless they are forced too.

The U.S. said it's decision was a moral one, a response to "extraordinary circumstances." Those extraordinary circumstances don't mean a thing to Moderna.
On that note, it's important to point out (as always) where the CEO made these comments: a first quarter earnings call.
4. It's on the U.S. to take the measures within its power to create the collaboration necessary to expand global manufacturing.

Moderna's CEO "quickly closed the door on providing tech transfer or monetary support to help a potential manufacturer make Moderna’s vaccine."
Of course he did. They won't do anything unless compelled. So, the U.S. has to compel them.
5. Moderna does not own all the relevant patents that go into its vaccine. The U.S. also has some.

"If the government successfully pursued its patent filings, the resulting patents would likely confer significant rights." - @PCMedsAccess
citizen.org/article/the-ni…
With comments like what we're seeing from Moderna's CEO, not pursuing ownership is an acknowledgement from the Biden admin that their stance on #TRIPsWaiver was more for show than for anything else.
endpts.com/moderna-ceo-br…
Publicity statements and gestures from pharmaceutical companies and governments won't end the pandemic. Immediate action will. (10/10)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Tahir Amin

Tahir Amin Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @realtahiramin

10 May
Talking of candour, the following few sentences in this letter that caught my attention in particular:

“The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials.”
“It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine.”
“Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk.”
Read 4 tweets
23 Nov 20
This @WSJ Editorial Board piece, which has the jingoism of Rudyard Kipling's writings, deserves a fuller response. But in this thread I'm going to focus on one particular sentence in the opinion to help enlighten the thinking of our 'friends' at the @WSJ. on.wsj.com/2IZPlFC
That sentence is:

"It’s not clear developing countries even have the ability to manufacture large-scale, complex technologies like Moderna’s mRNA vaccine or Eli Lilly’s monoclonal antibody cocktail—let alone distribute them."
Putting aside the @WSJ's superiority complex, it's worth looking at some examples in the past where similar statements made by those in the western hemisphere about the scientific/technological abilities of countries in the global south have been proven wrong.
Read 13 tweets
30 Sep 20
Despite what the CEO of Celgene/BMS has said in this hearing, it's important to note that even though Natco will enter with a generic version of Revlimid in 2022 it will be a very restricted amount.
The settlement between Natco/Celgene prevents Natco from fully coming to market until 2026. Other generics are still in litigation with Celgene BMS because of all the "important patent innovations" that Celegene piled up.
One of those "important innovations" is a patent on the crystalline form of lenalidomide which expires in 2027. A graduate student in organic chemistry would know how to get a crystalline form of a compound because it's just so obvious.
Read 4 tweets
30 Sep 20
The House Oversight Committee’s report on Celgene just dropped is a bombshell.

Internal strategy docs reviewed by Congress show that Celgene/BMS prioritised preventing “generic encroachment” and excluded competition by leveraging the U.S. patent system. oversight.house.gov/sites/democrat…
The report uses @IMAKglobal’s research to break down the details of Celgene/BMS’s patent abuse.

What is new are the insights we can take from the internal documents. Celgene knew the U.S. patent system could be manipulated, and they knew it gave them pricing control.
So, why, over 15 years, did their drug Revlimid go from $215 to $719/pill?

The report tells us what we already knew:

“pricing decisions...were driven almost exclusively by the need to meet company revenue targets and shareholder earnings goals.”
Read 4 tweets
29 Sep 20
Thread (1/14): Tomorrow, drugmakers will be testifying on the tactics the industry uses to prop up drug prices.

Let’s take a look at the story of a poster child of patent abuse: Celgene’s cancer drug Revlimid.
Currently, the list price for a 1-month supply of Revlimid is a staggering $22,314.

Revlimid is Celgene’s blockbuster moneymaker. In 2017, it brought in $8.1 billion — or 63% — of Celgene's revenue.

But, the real story of Revlimid starts back in the 1950s.
Revlimid began as the falsely proclaimed wonder drug Thalidomide, which was banished from the market in the early 60s after it was found to have devastating birth defects in the children of mothers who took it.
Read 14 tweets
6 Aug 20
Everyone in the #access2meds movement should see last week's tech hearings as a beacon. Monopolies have metastasized throughout our society thanks to a 40+ year economic agenda that has defined progress as giving power to a few. (1/5)
The hearings focused solely on tech, but just a peek at #pharma and one will quickly see the industry has all of the trappings of a monopolist’s candy store: widespread consolidation, the protections for perennial price increases, and most importantly...
...an antiquated patent system that provides pharma execs and their lawyer stonemasons the foundational bricks needed to fortify their revenue-generating “products” behind a facade of “innovation”.
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(